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Classification of Cardiomyopathies
Evolution or Revolution?
Perry M. Elliott, MBBS, MD
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Prof. Elliott
paper to dis“.I have attempted to maintain a proper balance
between man and his instruments,
between experienced opinion and statistics,
between traditional views and heterodox,
between bed-side medicine and special tests,
between the practical and the academic,
and so to link the past with the present.”dPaul Wood, OBE, MD (1)
Although it is not always appreciated, classiﬁcation
systems underpin virtually every aspect of our lives. The
methods used to describe complex systems vary according to
their primary purpose and the depth of understanding of the
systems themselves, and necessarily evolve with the accrual
of knowledge and changing needs in order to remain useful.
Classiﬁcations in medicine serve different purposes.
Perhaps the best known, the World Health Organization
International Classiﬁcation of Diseases, is designed for
morbidity and mortality reporting and in some countries is
used for reimbursement purposes (2). By contrast,See page 2046SNOMED Clinical Terms, or SNOMED CT, was created
in 1999 from the merger of SNOMED Reference Termi-
nology (SNOMED RT), developed by the College of
American Pathologists, and the Clinical Terms Version 3,
developed by the UK National Health Service in order to
improve patient care through the recording of detailed
clinical data and analysis of clinical processes (3). In this
issue of the Journal, Arbustini et al. (4) propose a coding
system inspired by these international standards for a very
speciﬁc group of cardiac diseasesdthe cardiomyopathies.
Their aim is to provide a precise, but adaptable, notation
that links etiology with clinical phenotypes and, by infer-
ence, treatment and prognosis. As the classiﬁcation of
cardiomyopathies has been the subject of 2 other indepen-
dent expert reviews in the United States and Europe rela-
tively recently (5,6), the obvious question is why do we need
a third report so soon?
Although much has been made about differences in
terminology, there is broad agreement that the generic termeart Hospital, University College London, London, United Kingdom.
has reported that he has no relationships relevant to the contents of this
close.cardiomyopathy refers to any disease of the myocardium that
cannot be explained by coronary artery narrowing or
abnormal loading of the ventricles. The arguments for the
exclusion of these common causes of myocardial disease have
been rehearsed elsewhere (5,6), but in essence, it is a prag-
matic attempt to focus clinical attention on disorders that
arise from within the cardiomyocyte or the extracellular
matrix. Over the past few decades, it has become apparent
that a substantial proportion of cardiomyopathies are caused
by single-gene defects affecting different aspects of
myocardial structure and function. With the exception of
a few founder mutations, the prevalence of individual genetic
mutations in most populations is relatively low, but in
aggregate, the frequency of genetic cardiomyopathies is
comparable to that of other common disorders, including
many cancers. For 50 years, clinicians have grouped
cardiomyopathies into subcategories on the basis of
ventricular morphology and function. This approach has
stood the test of time because it aligns very closely with
clinical presentation and therapeutic strategies, but it is
limited by the failure to consider etiology and by the
exclusion of mild or intermediate phenotypes that do not
meet conventional diagnostic criteria.
The system proposed by Arbustini et al. (4) is a valiant
attempt to capture the pathophysiological complexity of
cardiomyopathy in a single notation and represents a logical
progression from an iterative diagnostic pathway proposed in
a recent European Society of Cardiology working group
position statement in which conventional cardiological
assessments are combined with other noncardiac and
molecular parameters in a cardiomyopathy-focused approach
to diagnosis (7). At the heart of the scheme proposed by
Arbustini et al. (4) is the idea that clusters of clinical features
(or diagnostic “red ﬂags”) can be used to identify speciﬁc
genetic subtypes of cardiomyopathy that require individual-
ized management strategies; the clinical cases used to support
this argument represent some of the best examples of this.
The authors have clearly given much thought to the
design of the scheme and its ability to evolve with advancing
knowledge. However, there are number of aspects that need
further consideration. The ﬁrst is the category of morpho-
functional class or “M,” which attempts to summarize
informative phenotypic characteristics. At ﬁrst glance, this
is an innovative way of ﬂagging diagnostic clues such
as atrioventricular block and elevated serum creatine
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2074phosphokinase, but examples such as the notation for an
epsilon wave in arrhythmogenic right ventricular cardiomy-
opathy show how this approach could rapidly get out of
hand. The clinical phenotype of arrhythmogenic right
ventricular cardiomyopathy is highly complex and requires
analysis of dozens of clinical measurements (8); inclusion of
all such parameters in a single line of text, as implied by the
notation, would be impractical, at least in everyday clinical
practice. A related issue is the need for consistency in
coding, particularly in patients or relatives with “early
disease.” There is no doubt that many carriers of pathogenic
mutations have mild or intermediate phenotypes that are not
captured by standard deﬁnitions of disease. However, many
of the clinical traits seen in such individuals are nonspeciﬁc
or are conditional on factors such as age and sex (e.g., pre-
cordial T-wave inversion and mitral valve Doppler proﬁles).
Universal adoption of the nomenclature requires that all
users apply the same criteria, which in many cases have not
been established.
Finally, the concept of “stage” is difﬁcult to translate from
the cancer context. In the grading of tumors, staging is used
to plan treatment and to indicate prognosis. The challenge
in cardiomyopathy is to ﬁnd clinical parameters that fulﬁll
the same aims. The authors propose use of the American
College of Cardiology–American Heart Association stage
(A through D) and New York Heart Association (NYHA)
functional class (I to IV), but these are of limited use in some
settings. For example, NYHA functional class III symptoms
in a patient with hypertrophic cardiomyopathy and left
ventricular outﬂow tract obstruction do not necessarily imply
advanced end-stage disease with a poor prognosis. Similarly,
a patient with mild dilated cardiomyopathy caused by
a mutation in the lamin A/C gene may be at substantial risk
of sudden cardiac death and yet be entirely asymptomatic.
Staging based on symptoms alone is also challenged by the
fact that functional status varies spontaneously or in response
to treatment.
We live in an era of breathtaking scientiﬁc discovery
driven by the ability to study complex systems using high-
throughput technologies and sophisticated analytical tools.
In the medical sciences, this is exempliﬁed by emergence
of whole new specialties such as genomics and proteomics.
The scheme proposed by Arbustini et al. (4) representsa potential bridge between these new scientiﬁc disciplines
and clinical medicine, but before it can be adopted, its
primary purpose needs to be very precisely deﬁned and its
performance as a diagnostic and prognostic tool prospec-
tively tested. For the moment, its most important contri-
bution is to remind us that improvements in health come
through the integration of basic science with the craft of
clinical medicine.
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